Real-world experience with subcutaneous infliximab: broadening treatment strategies for inflammatory bowel disease

Smith, Philip J.; Fuméry, Mathurin; Leong, Rupert W.; Novak, Kerri L.; Dignaß, Axel

doi:10.1080/1744666x.2023.2231148

Cited by 5 publications

(1 citation statement)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They suggested that, due to its low immunogenicity, SC infliximab can be used to reinduce therapy in refractory CD patients with positive neutralizing anti-infliximab antibodies [8]. Other real-world data further substantiate the evidence for both infliximab and vedolizumab [6,7,20].…”

Section: Discussionmentioning

confidence: 97%

Switching from Intravenous to Subcutaneous Biological Therapy for Inflammatory Bowel Disease Patients Remains a Challenge

Richter,

Cohen,

Kriger-Sharabi

et al. 2024

JCM

View full text Add to dashboard Cite

Biological inflammatory bowel disease (IBD) medications, once limited to intravenous (IV) administration, can now be administered both via IV and subcutaneously (SC). This study investigates patient preferences, willingness to switch from IV to SC, and associated factors. A questionnaire covering demographics, disease-related inquiries, quality of life, and IBD medication preferences was distributed via email, the Israeli Crohn’s Disease and Ulcerative Colitis Foundation, infusion centers, and clinics. From 454 IBD patients (median age: 42 years; 55.7% female), responses revealed a preference for SC every 8 weeks, which is comparable to daily oral dosing. Both options were significantly favored over IV every 8 weeks and SC every 2 weeks, with no statistically significant differences between the latter two. However, among patients who were experienced with both SC and IV administration, a clear preference for SC administration every 2 weeks over IV every 8 weeks surfaced. Among IV-treated patients, 54.5% resisted switching to SC. Key reasons for this included medical staff presence (57.7%), a fear of needles (46.4%), belief in infusion efficacy (37.1%), and longer intervals between infusions (36.1%). Findings suggest that transitioning from IV to SC treatment is challenging due to patient resistance, which is influenced by specific factors. Identifying and addressing these obstacles is crucial for optimizing IBD management.

show abstract